Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-finding trial of SSP-002358 plus PPI in GERD with persistent regurgitation
2011-004388-62Phase 2Completed
- Sponsor
- Movetis
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of revexepride in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Movetis. Primary endpoint: Percentage of regurgitation-free days. Started Apr 2012; status: completed.
02
Drugs
revexepride
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2011-004388-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004388-62.